ClinicalTrials.gg
Not yet recruitingNCT07550374Updated Apr 24, 2026

Phase I Clinical Study of NouvNeu001 Injection for the Treatment of Moderate-to-Advanced Parkinson's Disease in Patients Who Have Previously Undergone Deep Brain Stimulation or Deep Brain Nucleus Lesioning Surgery

A Phase 1 interventional study of NouvNeu001 injection in Parkinson's Disease (PD), sponsored by iRegene Therapeutics Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-04-24.

Sponsored by iRegene Therapeutics Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 279 studies in Parkinson Disease with a site in China — 128 open to participants now, 135 under way, 3 of them phase 3. Parkinson Disease · China.

Planned enrollment
186th of 211
10 · median 47
Started
2026
with 40 others
Phase 1
39 of 279
22 open now
Primary completion
2028-04
later than 112 of 134 live
Registered
248th of 279
by date

Among the 279 studies in Parkinson Disease with a site in China, this one is the 186th largest by planned enrollment of the 211 interventional ones that give a count, is one of 41 that started in 2026, is one of 39 in phase 1, reaches primary completion later than 112 of the 134 other live ones, and was the 248th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

128 of the 279 studies in Parkinson Disease with a site in China are open now. Recruiting first, the newest first:

123 more — sign in →

All 128 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 279 studies in Parkinson Disease with a site in China, or all of them as a file.
02

Study summary

This clinical trial is designed to evaluate the safety, tolerability and preliminary efficacy of a single injection of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in patients with Parkinson's Disease who have previously undergone deep brain stimulation or deep brain nucleus lesioning surgery.

03

Conditions studied

  • Parkinson's Disease (PD)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years and ≤70 years, male or female.
  2. The subject understands and agrees to comply with the study procedures, voluntarily participates, and signs the form.
  3. Primary Parkinson's disease (meeting the diagnostic criteria of the International Parkinson and Movement Disorder Society [MDS]), and the subject has previously undergone deep brain stimulation (DBS) or deep brain nucleus lesioning surgery.
  4. With DBS turned off, the MDS Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS-III) motor examination score in the "off" state is ≥30; and the levodopa challenge test is positive (improvement rate in UPDRS-III score ≥30%).
  5. Able to undergo neurosurgery under anesthesia, and able to undergo CT/MRI/PET examinations.
  6. At screening, with DBS turned on, the modified Hoehn and Yahr stage (Appendix 3) in the "off" state is between 2.5 and 4 (inclusive), and with DBS turned on, the daily "off" time is not less than 2 hours.
  7. Has received stable doses of anti-Parkinson's disease medications for at least 4 weeks prior to administration.
  8. Acceptable laboratory values obtained during the screening period and prior to administration (Day 0): ≥ lower limit of normal (LLN); White blood cell count ≥ LLN; count ≥ LLN; and ALT ≤ 2.5 × (ULN); Total ≤ 1.5 × ULN; Serum creatinine ≤ 1.5 × ULN; ≥ 50 mL/min/1.73 m².
  9. The subject agrees to postpone any other elective neurosurgical procedures until completion of the 12-month follow-up study.
  10. The subject agrees not to participate in any other interventional clinical studies within 12 months after administration.
  11. The subject agrees not to receive any vaccines within 30 days after administration.

Exclusion criteria

Exclusion Criteria:

  1. Atypical or secondary parkinsonism confirmed by the investigator to be caused by medication, metabolic disorders, or other conditions.
  2. Presence of persistent active infection in the previous brain surgery area, cerebrospinal fluid (CSF) leakage, or unhealed wounds; presence of implanted device malfunction, electrode displacement, etc., which in the investigator's judgment poses a significant risk to the subject or affects evaluation; to MRI (e.g., intracranial implants, cochlear implants, cardiac pacemaker/defibrillator, etc.); any contraindications to surgery or anesthesia as assessed by the investigator; or other surgical conditions that the investigator believes may affect participation in this study.
  3. Significant abnormalities on cranial CT/MRI, including but not limited to: cerebral vascular malformation, vasogenic edema, brain tumor, more than 10 microbleeds, basal ganglia cerebral infarction lesions, etc., which in the investigator's judgment significantly increase surgical risk.
  4. History of severe cardiovascular disease within 1 year prior to screening, including but not limited to: severe heart failure ( Class III or IV, or \<35% by any method), unstable angina pectoris, myocardial infarction, conduction abnormalities (e.g., unstable atrial fibrillation), etc., which in the investigator's judgment may increase surgical risk or render the subject unsuitable for participation.
  5. History of malignant tumor, or receipt of cell therapy or gene therapy within 2 years prior to screening.
  6. Active disseminated intravascular coagulation (DIC) or significant bleeding tendency within 3 months prior to signing , or inability to discontinue antiplatelet or other anticoagulant medications for at least 5 days before surgery.
  7. Long-term (≥14 days) and high-dose (prednisone ≥20 mg/day or equivalent dose of other ) use of glucocorticoids or (excluding topical use) within 3 months prior to signing informed consent.
  8. History of psychiatric illness that, in the investigator's judgment, makes the subject unsuitable for participation; or history of suicidal ideation or suicidal attempt (including actual attempt, interrupted attempt, or aborted attempt) within the past year or currently.
  9. Use of botulinum toxin within 6 months prior to signing informed consent.
  10. Active epilepsy or current use of antiepileptic drugs at screening.
  11. History of dementia or severe cognitive impairment; or obvious dementia or cognitive impairment at screening; MDS-UPDRS Part 1.1 (cognitive impairment) score >3 at screening; poor compliance, inability to accurately complete diaries, and/or inability to sign informed consent due to dementia.
  12. Severe depression, anxiety, or severe dysphagia at screening.
  13. Any of the following abnormal laboratory findings at screening, including but not limited to: Clinically significant abnormalities in coagulation function ( ≥1.5 × , activated partial thromboplastin time ≥1.5 × ULN); Clinically significant immunological abnormalities or disease, assessed by the investigator as unsuitable for trial participation; Poorly controlled hypertension (defined as blood pressure still >160/100 mmHg despite antihypertensive treatment) and severe orthostatic hypotension; Poorly controlled diabetes mellitus ( >9.0%, or fasting plasma glucose [FPG] ≥11.1 mmol/L).
  14. Other severe systemic diseases, such as cor pulmonale, severe (COPD) (% \<50%), etc.
  15. Presence of (HIV) infection, syphilis infection, active virus (HCV) infection, virus (HBV) infection, tuberculosis infection, or other active infections that the investigator believes may affect the subject's participation in the study or influence study outcomes.
  16. Alcohol dependence, or positive drug abuse screening.
  17. Contraindication or history of allergy to medications used during the study (e.g., tacrolimus, levodopa, etc.) or any of their components; allergy to the above drugs, other macrolide drugs; or allergic constitution (e.g., allergy to two or more drugs or foods).
  18. Women of childbearing age who have not undergone sterilization/are not /are unwilling to use medically recognized effective for 2 years after study drug administration, and breastfeeding women; men who have not undergone sterilization/are unwilling to use medically recognized effective contraception for 2 years after study drug administration.
  19. Receipt of electroconvulsive therapy within 30 days prior to administration.
  20. Currently participating in another clinical trial, or having participated in another clinical study and received interventional treatment within 3 months prior to administration.
  21. Severe dyskinesia in both medication "on" and "off" states.
  22. Serious illness, or poor compliance as judged by the investigator, or any other condition that the investigator believes may jeopardize subject safety or affect study evaluation.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    NouvNeu001

    Low-dose and high-dose groups are set, with 5 subjects in each dose group. All eligible subjects who are screened and successfully enrolled will receive a single administration of NouvNeu001 injection during the surgical period, delivered via stereotactic neurosurgical injection into the bilateral putamen/striatum.

    Biological: NouvNeu001 injection

Interventions

  • BiologicalNouvNeu001 injection

    NouvNeu001 injection is a Human Dopaminergic Progenitor Cell injection, administered as a single injection into the putamen/striatum region of the brain.

06

What researchers measure

Primary outcomes

  1. Incidence and severity of Adverse Events as Assessed by CTCAE V5.0

    Incidence and severity of adverse events (AEs) and serious adverse events (SAEs).

    Time frame: 48 weeks post-transplant

Secondary outcomes

  1. Changes from baseline in the MDS Unified Parkinson's Disease Rating Scale (MDS-UPDRS) total score, as well as MDS-UPDRS Parts I, II, III (off state and on state), and IV scores at 12, 24, 36, 48, 72, and 96 weeks after administration.

    Change from baseline in the MDS Unified Parkinson's Disease Rating Scale (MDS-UPDRS) total score (Part I Score 0 \~ 52 + Part II Score 0 \~ 52 + Part III Score 0 \~ 72 + Part IV Score 0 \~ 24) at Weeks 12, 24, 36, 48, 72, and 96. A higher score indicates more severe symptoms or worse health.

    Time frame: Weeks 12, 24, 36, 48, 72, and 96

  2. Changes from baseline in the Modified Hoehn and Yahr Staging at 12, 24, 36, 48, 72, and 96 weeks after administration

    Change from baseline in the Modified Hoehn and Yahr Staging (0, 1, 1.5, 2, 2.5, 3, 4, 5) at Weeks 12, 24, 36, 48, 72, and 96. A higher Stage indicates more severe symptoms or worse health.

    Time frame: Weeks 12, 24, 36, 48, 72, and 96

  3. Changes from baseline in the Hamilton Depression Rating Scale (HAMD) score at 12, 24, 36, 48, 72, and 96 weeks after administration

    Change from baseline in the Hamilton Depression Rating Scale (HAMD) score (0 \~ 53) at Weeks 12, 24, 36, 48, 72, and 96. A higher score indicates more severe symptoms or worse health.

    Time frame: Weeks 12, 24, 36, 48, 72, and 96

  4. Changes from baseline in the Parkinson's Disease Questionnaire (PDQ-39) score at 12, 24, 36, 48, 72, and 96 weeks after administration

    Change from baseline in the Parkinson's Disease Questionnaire (PDQ-39) score (0 \~ 156) at Weeks 12, 24, 36, 48, 72, and 96. A higher score indicates more severe symptoms or worse health.

    Time frame: Weeks 12, 24, 36, 48, 72, and 96

  5. Changes from baseline in "off" time and "on" time at 12, 24, 36, 48, 72, and 96 weeks after administration

    Change from baseline in the "off" time and "on" time at Weeks 12, 24, 36, 48, 72, and 96. The shorter the "on" time, the longer the "off" time indicates more severe symptoms or worse health.

    Time frame: Weeks 12, 24, 36, 48, 72, and 96

  6. Changes from preoperative baseline in the daily oral levodopa equivalent dose (LEDD) of patients at 12, 24, 36, 48, 72, and 96 weeks after administration

    Change from baseline in the daily oral levodopa equivalent dose (LEDD) of patients at Weeks 12, 24, 36, 48, 72, and 96, A higher LEDD value indicates that the patient has used a larger dose of levodopa-class medications.

    Time frame: Weeks 12, 24, 36, 48, 72, and 96

  7. Changes from baseline in Total Electrical Energy Delivered (TEED) at 12, 24, 36, 48, 72, and 96 weeks after administration

    Change from baseline in Total Electrical Energy Delivered (TEED) at Weeks 12, 24, 36, 48, 72, and 96. A higher TEED value indicates that the patient has received a greater amount of electrical stimulation

    Time frame: Weeks 12, 24, 36, 48, 72, and 96

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Apr 2028, 23 months later.

Of 127 industry-sponsored phase 1 interventional studies under Parkinson Disease, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 24. This study's planned 23 months is above that.

Counting every sponsor, half of 204 studies reached it within 18 months; a quarter within 5 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2026
First posted
Apr 24, 2026
StartEst.
May 2026
Primary completionEst.
Apr 2028
CompletionEst.
Jul 2031
Last update
Apr 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07550374
Lead sponsor
iRegene Therapeutics Co., Ltd.
Responsible party
Sponsor
First posted
Apr 24, 2026
Start date
May 2026 (estimated)
Primary completion
Apr 2028 (estimated)
Completion
Jul 2031 (estimated)
Last update
Apr 24, 2026

Study contacts

Meng Cai, Ph.D
Contact
caimeng@iregene.com
0086-027-59337986

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion